Drug Discovery World

MAY 16, 2023

The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).

Production 52

Production Gene Therapy Gene Bioinformatics 52

Drug Discovery World

FEBRUARY 8, 2024

The event aimed to help the audience understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product for enhanced therapeutic development. Dr O’Hara also provided an AAV plasmid preparation case study. Why are those important?

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

Drug Discovery World

OCTOBER 3, 2023

The event aimed to help the audience understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product for enhanced therapeutic development. Dr O’Hara also provided an AAV plasmid preparation case study. Why are those important?

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

The Pharma Data

SEPTEMBER 11, 2021

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Antibody 52

Antibody DNA Containment Manufacturing 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions. Industry 4.0’

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

DECEMBER 13, 2023

Modern is making significant strides in advancing its mRNA technology and diversifying its product portfolio to address a broad spectrum of medical conditions. Dynavax boasts two successful commercial products in its portfolio. Notably, R&D expenditures for the second quarter of 2023 surged by 62 percent to reach $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.

Genome 52

Genome Genomics RNA Genome Project 52